FDA Approves Sanofi's Infilbray, First Therapy for Gaucher Type 3 Brain Symptoms
FDA approves Sanofi's Infilbray (venglustat), the first therapy for neurological symptoms of Gaucher disease type 3, adding a third product to a Gaucher franchise worth over €1 billion in 2025 sales.
TAG T-5371 · 710 words on the filing

Summary of findings
- FDA approved Infilbray (venglustat) on Wednesday as the first therapy for neurological manifestations of Gaucher disease type 3.
- Approval covers adults and children weighing at least 15 kg, based on statistically significant one-year Phase 3 results on neurological measures.
- Cerezyme and Cerdelga generated more than €1 billion (about $1.1 billion) in global sales for Sanofi in 2025.
- Label warns of increased risk of suicidal thoughts and behavior; common adverse events include diarrhea and nausea.
- Drug remains under review in Europe and Japan; a Phase 3 test in Fabry disease failed last year.
The FDA on Wednesday approved Sanofi's Infilbray, the first therapy for the neurological manifestations of Gaucher disease type 3. The drug, known in development as venglustat, becomes the first approved treatment able to cross the blood-brain barrier and address the source of the cognitive and movement symptoms of this rare inherited disease.
The approval covers adults and children weighing at least 15 kg, roughly 33 pounds. Sanofi will commercialize the small molecule under the brand name Infilbray.
What is the disease and how does the drug work?
Gaucher disease stems from mutations in the GBA1 gene. The mutations cause a deficiency of glucocerebrosidase, an enzyme that breaks down fatty molecules called glycosphingolipids. Without sufficient enzyme, those lipids accumulate in organs throughout the body.
The disease has three types. In type 3, lipid buildup in the central nervous system drives dementia and loss of muscle control. Patients also suffer systemic problems, including enlargement of the liver and spleen. Infilbray blocks an enzyme central to glycosphingolipid synthesis, cutting the production of the lipids at their source rather than replacing the missing enzyme.
That mechanism distinguishes it from every other approved Gaucher therapy on the market today.
What did the Phase 3 trial show?
The approval rests on a Phase 3 test in adults and pediatric patients aged 12 and older with Gaucher type 3. All enrolled patients had already achieved systemic disease stabilization with prior enzyme replacement therapy.
The trial compared daily oral doses of the study drug against intravenous enzyme replacement therapy administered every two weeks. At one year, Infilbray showed statistically significant improvement on a test assessing multiple neurological measures. Sanofi did not disclose the specific endpoint values or P-values in the announcement.
The most common adverse events in the trial were diarrhea, enlarged spleen and nausea. The label also carries a warning that the drug may increase the risk of suicidal thoughts and behavior, a signal prescribers will need to monitor in a chronic-use pediatric population.
The one-year data position an oral therapy as a potential replacement for biweekly infusions in stabilized patients.
How does Infilbray fit Sanofi's Gaucher franchise?
Sanofi already holds a leading position in Gaucher. Its enzyme replacement therapy Cerezyme competes against enzyme replacement products from Takeda Pharmaceutical and Pfizer. All three products carry approvals in Gaucher type 1.
Earlier this year, Cerezyme received a label expansion covering the non-neurological symptoms of Gaucher type 3 in adults. That U.S. decision arrived nearly 30 years after the therapy won approval in the same indication in Europe.
Sanofi also sells Cerdelga, an oral drug approved in 2014 for adults with type 1. Both Cerezyme and Cerdelga came from Genzyme, which Sanofi acquired in 2011. The two products generated more than €1 billion, about $1.1 billion, in global sales in 2025. Infilbray, another Genzyme-derived asset, gives Sanofi a third product in the franchise and its first neurological claim in the disease.
What did clinicians say about the approval?
Dr. Pramod Mistry, director of the Yale Lysosomal Disease Center and Gaucher Disease Treatment Center, framed the approval as filling a long-standing treatment gap. "We have been able to treat the systemic manifestations of type 3 Gaucher disease, while the neurological manifestations remained beyond the reach of available therapies," Mistry said in Sanofi's announcement.
"The availability of a medicine capable of addressing the neurological manifestations of this devastating disorder represents a major milestone for patients, families, and the global type 3 Gaucher disease community," he said.
What comes next for venglustat?
The Gaucher type 3 approval is not the end of the regulatory road. Sanofi said the drug remains under regulatory review in Europe and Japan for the same indication. The company plans submissions in additional markets over the coming year.
The program also carries a recent setback. Last year, Sanofi reported that the molecule failed to meet the goals of a Phase 3 test in Fabry disease, another rare enzyme deficiency. The Gaucher result nonetheless validates the substrate-reduction approach in the central nervous system, an area where enzyme replacement cannot reach. Sanofi has converted a Genzyme discovery into the first therapy that reaches the brain in a disease where dementia and motor decline had no approved answer.
via fda.gov (Original)
More from Grace Kim
Show full bio
Market editor covering companies, deals and strategy in global pharmaceutical industry at PharmInsider.
11 articles
Linked filings
- C-7292
- T-8005
- V-8328
- K-3717
- V-5496